期刊文献+

托烷司琼与帕洛诺司琼预防化疗胃肠道反应的成本-效果分析 被引量:16

he Cost-Effectiveness Analysis of Tropisetron and Palonosetron in Preventing Gastrointestinal Side Effects after Chemotherapy
下载PDF
导出
摘要 目的:比较托烷司琼与帕洛诺司琼预防化疗胃肠道反应的疗效及成本-效果。方法:选取60例采用吉西他滨+顺铂方案化疗的局部晚期非小细胞肺癌患者,将其按随机数字表法分为两组(帕洛诺司琼组和托烷司琼组),分别给予托烷司琼和帕洛诺司琼止吐处理,观察相关疗效及运用药物经济学成本-效果分析法进行评价。结果:帕洛诺司琼与托烷司琼在治疗急性呕吐控制方面,其有效率比较差异无统计学意义(P<0.05);但在恶心程度的控制上,帕洛诺司琼的有效率为73.3%,每周期化疗人均止吐药物成本为(718.00±0.49)元,有效率每增加1个百分点,成本为(9.79±0.08)元;托烷司琼的有效率为43.3%,每周期化疗人均止吐药物成本为(692.48±0.52)元,有效率每增加1个百分点,成本为(15.99±0.11)元。以低成本(托烷司琼)为参照,帕洛诺司琼组与之对比增加的成本-效果比为(0.85±0.61)元。两组患者均未发现不良反应。结论:帕洛诺司琼治疗化疗胃肠道反应疗效优于托烷司琼,成本-效果比亦优于托烷司琼。 Objective:To compare efficacy and cost-effectiveness of tropisetron and palonosetron preventing gastrointestinal side effects of chemotherapy. Method:60 patients treated with gemcitabine and cisplatin chemotherapy for locally advanced non-small cell lung cancer were randomly divided into two groups according to random number table method,were treated with tropisetron and palonosetron. The efficacy and costs-effectiveness analysis with pharmacoeconomics were evaluated. Result:There was no significant difference in controlling acute vomiting between the two groups(P〉0.05). Efficiency rate of palonosetron in the control of nausea was 73.3%,antiemetic drug costs each cycle of chemotherapy was(718 ± 0.49)yuan,efficiency of each increase of 1 percentage points,the cost was(9.79 ± 0.08)yuan;Efficiency rate of tropisetron in the control of nausea was 73.3%,antiemetic drug costs each cycle of chemotherapy was(718 ± 0.49)yuan,efficiency of each increase of 1 percentage points,the cost was(9.79 ± 0.08)yuan. At low cost(tropisetron)as the reference,the increase cost of the palonosetron group was(0.85 ± 0.61)yuan. Adverse reactions were not found in the two groups. Conclusion:Palonosetron is more effective than tropisetron in preventing gastrointestinal reactions of chemotherapy and the cost-effectiveness ratio is also superior to tropisetron.
出处 《中国医学创新》 CAS 2014年第2期116-118,共3页 Medical Innovation of China
关键词 托烷司琼 帕洛诺司琼 化疗 成本-效果分析 Tropisetron Palonosetron Chemotherapy Cost-effectiveness analysis
  • 相关文献

参考文献11

二级参考文献41

共引文献463

同被引文献129

  • 1于波.顺铂分次给药在肺癌化疗中的临床观察[J].现代医药卫生,2005,21(18):2469-2470. 被引量:2
  • 2王金彩,郑继海,李小瑞.托烷司琼预防含顺铂化疗药物所致恶心、呕吐的临床观察[J].中国医药导报,2007,4(03X):14-15. 被引量:10
  • 3王贤成,潘良熹.不同用法顺铂的CAP方案治疗非小细胞肺癌临床观察[J].河南肿瘤学杂志,1997,10(1):63-64. 被引量:2
  • 4国家药典委员会.中国药典·临床用药须知[S].北京:中国医药科技出版社,2010:389-391.
  • 5Carnio S,Novello S,Mele T,et al.Extending survival of stageⅣnon-small cell lung cancer[J].Semin Oncol,2014,41(1):69.
  • 6Johnson DH,Schiller JH,Bunn PA Jr.Recent clinical advances in lung cancer management[J].J Clin Oncol,2014,32(10):973.
  • 7Bussel JB,Lakkaraja M.Thrombopoietic agents:there is still much to learn[J].Presse Med,2014,43(4 Pt 2):69.
  • 8Baykara M,Coskun U,Berk V,et al.Gemcitabine plus paclitaxel as second-line chemotherapy in patients with advanced non-small cell lung cancer[J].Asian Pac J Cancer Prev,2012,13(10):5119.
  • 9Vadhan-Raj S.Management of chemotherapy-induced thrombocytopenia:current status of thrombopoietic agents[J].Semin Hematol,2009,46(1 Suppl 2):26.
  • 10Wu S,Zhang Y,Xu L,et al.Multicenter,randomized study of genetically modified recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in cancer patients receiving chemotherapy[J].Support Care Cancer,2012,20(8):1 875.

引证文献16

二级引证文献81

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部